Steady Expansion Forecast for Anaphylaxis Treatment Market, Projected to Reach $8.72 Billion by 2029

Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.

Anaphylaxis Treatment Market Size Valuation Forecast: What Will the Market Be Worth by 2025?
In recent years, the anaphylaxis treatment market has seen significant growth. It is projected to expand from $6.19 billion in 2024 to $6.61 billion in 2025, representing a compound annual growth rate (CAGR) of 6.9%. Factors contributing to the growth observed in the historical period include a rise in allergic reaction incidences, broader acknowledgment of anaphylaxis, increased accessibility of epinephrine auto-injectors, heightened public consciousness and education, and improved healthcare professional training.

Anaphylaxis Treatment Market Size Forecast: What's the Projected Valuation by 2029?
The market for anaphylaxis treatment is projected to undergo substantial expansion in the upcoming years. It is forecasted to attain a value of $8.72 billion by 2029, with a compound annual growth rate (CAGR) of 7.2%. The projected growth for the period can be linked to advances in biologic therapies, personalized treatment strategies, international food safety initiatives, patient activism and empowerment, as well as improved emergency medical services. Auto-injector innovation, utilization of telemedicine for managing anaphylaxis, advancements in allergen immunotherapy, biometric wearable technology for allergen detection, and research collaborations in the field of allergy are among the significant trends expected during the forecast period.

View the full report here:
https://www.thebusinessresearchcompany.com/report/anaphylaxis-treatment-global-market-report

What Are the Drivers Transforming the Anaphylaxis Treatment Market?
An increasing incidence of food allergies is anticipated to fuel the expansion of the anaphylaxis treatment market. Food allergies occur when the immune system reacts to proteins present in food. Anaphylaxis treatment intervenes to halt the advancement of fatal allergic symptoms which can affect the skin, mucosal surfaces, respiratory system, hypotension, and end-organ dysfunction. In January 2023, the Centers for Disease Control and Prevention, a US government agency, reported that in 2021, 31.8% of adults over 18 had experienced eczema, seasonal allergies, or a food allergy. A quarter (25.7%) of adults had seasonal allergies, 6.2% had food allergies, and 7.3% had eczema. Moreover, in August 2024, the Food Standards Agency, a non-ministerial department in the UK, received 296 valid reports to the Registry from October 2021 to August 27, 2023, likely accounting for less than 5% of unintentional reactions in the UK. 213 (72%) of these incidents were food-related, and 97.7% involved children and young people aged 18 or under, with only 28 clinics and 11 Accident & Emergency (A&E) departments registering for platform access. As a result, the growing prevalence of food allergies is driving the anaphylaxis treatment market's growth.

Get your free sample here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12105&type=smp

What Long-Term Trends Will Define the Future of the Anaphylaxis Treatment Market?
The trend of evolving product development stands out in the anaphylaxis treatment market. In order to maintain their market standing, key companies are making strides in refining their products. A case in point is Aquestive Therapeutics Inc., a pharmaceutical company based in the US, which has been granted Fast Track designation from the Food and Drug Administration for AQST-109, a treatment for severe allergic reactions, including anaphylaxis, in April 2022. The company is pressing ahead with clinical trials for AQST-109, which stands out as the first and only orally administered epinephrine product contender that has shown comparable clinical results to auto-injector alternatives such as EpiPen and Auvi-Q in treating allergic emergencies, including anaphylaxis.

Which Segments in the Anaphylaxis Treatment Market Offer the Most Profit Potential?
The anaphylaxis treatment market covered in this report is segmented -

1) By Treatment: Epinephrine, Antihistamines, Steroids, Beta-antagonists, Other Treatments
2) By Product: Tablets, Capsules, Other Products
3) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy
4) By Application: Food Allergy, Pollen Allergy, Dust Mites Allergy, Other Applications

Subsegments:
1) By Epinephrine: Auto-Injectors, Vials Or Syringes
2) By Antihistamines: Oral Antihistamines, Injectable Antihistamines
3) By Steroids: Oral Steroids, Injectable Steroids
4) By Beta-antagonists: Oral Beta-blockers, Injectable Beta-blockers
5) By Other Treatments: Corticosteroids, Intravenous Fluids, Other Supportive Treatments

Tailor your insights and customize the full report here:
https://www.thebusinessresearchcompany.com/customise?id=12105&type=smp

Which Firms Dominate the Anaphylaxis Treatment Market by Market Share and Revenue in 2025?
Major companies operating in the anaphylaxis treatment market include Merck & Co. Inc., Novartis International AG, GlaxoSmithKline plc, Viatris Inc., Teva Pharmaceutical Industries Ltd., Mylan N.V., Bausch Health Companies, Sun Pharmaceutical Industries Ltd., Perrigo Co, Dr. Reddy's Laboratories Ltd., Hikma Pharmaceuticals plc, Amneal Pharmaceuticals Inc., ALK-Abelló A/S, Amphastar Pharmaceuticals Inc., Par Pharmaceutical Inc., Genentech Inc., Meridian Medical Technologies LLC, Aquestive Therapeutics Inc., Sandoz Inc., Adamis Pharmaceutical Corporation, Impax Laboratories LLC

Which Regions Offer the Highest Growth Potential in the Anaphylaxis Treatment Market?
North America was the largest region in the anaphylaxis treatment market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the anaphylaxis treatment market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Purchase the full report today:
https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=12105

This Report Supports:
1. Business Leaders & Investors - To identify growth opportunities, assess risks, and guide strategic decisions.
2. Manufacturers & Suppliers - To understand market trends, customer demand, and competitive positioning.
3. Policy Makers & Regulators - To track industry developments and align regulatory frameworks.
4. Consultants & Analysts - To support market entry, expansion strategies, and client advisory work.

Connect with us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company,
Twitter: https://twitter.com/tbrc_info,
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ.

Contact Us
Europe: +44 207 1930 708,
Asia: +91 88972 63534,
Americas: +1 315 623 0293 or
Email: mailto:info@tbrc.info

Learn More About The Business Research Company
With over 15,000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Our flagship product, the Global Market Model delivers comprehensive and updated forecasts to support informed decision-making.

This release was published on openPR.